Dr. Nadine Tung (IMAGE)
Caption
“Neoadjuvant treatment with 12 weeks of THP led to a pCR rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer at the time of surgery, compared to 33% for those with ER-positive tumors,” said lead investigator Nadine M. Tung, MD, a medical oncologist at Beth Israel Deaconess Medical Center in Boston (pictured). “We also found that among ER-positive breast cancers, lower level of ER expression resulted in higher pCR rates.”
Credit
Beth Israel Deaconess Medical Center
Usage Restrictions
No restrictions.
License
Public Domain